ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the US, providing a new option ...

Neffy ® (epinephrine nasal spray) 1mg is now available for the ... prepare for allergic emergencies,” said Eric Karas, Chief Commercial Officer of ARS Pharma. “The needle-free design of ...

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

Kindeva, a global contact development and manufacturing organization, was joined by Lieutenant Governor Jacqueline Coleman ...

Discover AQST's growth potential with Anaphylm's FDA approval by Q2'25 targeting $1B revenue. Learn DCF valuations offering ...

Indivior PLC’s recovery hinges on Sublocade’s momentum and market trends, though risks persist in litigation and earnings.

Akita Biosciences, Inc., a consumer health company that develops innovative nasal spray formulations for drug, device, and cosmetic applications, has received a grant from Flu Lab to evaluate the ...

Danish allergy immunotherapy specialist ALK Abello (OMX: ALK B) has announced a four-year agreement with USA-based ARS ...

(epinephrine nasal spray), the only approved needle-free treatment ... We also anticipate broadening unrestricted commercial access for is indicated for emergency treatment of type I allergic ...

Control Bionics, LTR Pharma and Lumos Diagnostics are among ASX health companies reporting strong quarterly results this week ...

ARS Pharma enters agreement with ALK-Abelló to co-promote neffy, a needle-free treatment for type I allergic reactions: San Diego Monday, May 5, 2025, 12:00 Hrs [IST] ARS Pharmac ...